Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PRKCI_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRKCI_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKCI_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PRKCI_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKCI_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PRKCI_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PRKCI_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKCI_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00182096 | Cervix | CC | peptidyl-serine modification | 66/2311 | 338/18723 | 9.58e-05 | 1.25e-03 | 66 |
GO:00072194 | Cervix | CC | Notch signaling pathway | 39/2311 | 172/18723 | 1.08e-04 | 1.38e-03 | 39 |
GO:19030768 | Cervix | CC | regulation of protein localization to plasma membrane | 27/2311 | 104/18723 | 1.15e-04 | 1.44e-03 | 27 |
GO:00434349 | Cervix | CC | response to peptide hormone | 77/2311 | 414/18723 | 1.40e-04 | 1.70e-03 | 77 |
GO:00085933 | Cervix | CC | regulation of Notch signaling pathway | 25/2311 | 95/18723 | 1.61e-04 | 1.93e-03 | 25 |
GO:00481938 | Cervix | CC | Golgi vesicle transport | 58/2311 | 296/18723 | 2.24e-04 | 2.54e-03 | 58 |
GO:19043758 | Cervix | CC | regulation of protein localization to cell periphery | 30/2311 | 125/18723 | 2.28e-04 | 2.56e-03 | 30 |
GO:00713757 | Cervix | CC | cellular response to peptide hormone stimulus | 57/2311 | 290/18723 | 2.32e-04 | 2.59e-03 | 57 |
GO:190121410 | Cervix | CC | regulation of neuron death | 61/2311 | 319/18723 | 3.11e-04 | 3.31e-03 | 61 |
GO:005140210 | Cervix | CC | neuron apoptotic process | 49/2311 | 246/18723 | 4.48e-04 | 4.48e-03 | 49 |
GO:00328698 | Cervix | CC | cellular response to insulin stimulus | 42/2311 | 203/18723 | 4.95e-04 | 4.83e-03 | 42 |
GO:00510915 | Cervix | CC | positive regulation of DNA-binding transcription factor activity | 51/2311 | 260/18723 | 5.05e-04 | 4.92e-03 | 51 |
GO:00519603 | Cervix | CC | regulation of nervous system development | 77/2311 | 443/18723 | 1.13e-03 | 9.30e-03 | 77 |
GO:00328688 | Cervix | CC | response to insulin | 50/2311 | 264/18723 | 1.28e-03 | 1.02e-02 | 50 |
GO:00507676 | Cervix | CC | regulation of neurogenesis | 65/2311 | 364/18723 | 1.33e-03 | 1.05e-02 | 65 |
GO:19054758 | Cervix | CC | regulation of protein localization to membrane | 36/2311 | 175/18723 | 1.33e-03 | 1.05e-02 | 36 |
GO:19040194 | Cervix | CC | epithelial cell apoptotic process | 27/2311 | 121/18723 | 1.49e-03 | 1.16e-02 | 27 |
GO:00510923 | Cervix | CC | positive regulation of NF-kappaB transcription factor activity | 32/2311 | 152/18723 | 1.62e-03 | 1.25e-02 | 32 |
GO:00435238 | Cervix | CC | regulation of neuron apoptotic process | 41/2311 | 212/18723 | 2.23e-03 | 1.60e-02 | 41 |
GO:00507694 | Cervix | CC | positive regulation of neurogenesis | 43/2311 | 225/18723 | 2.25e-03 | 1.61e-02 | 43 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKCI | SNV | Missense_Mutation | | c.1540N>C | p.Ala514Pro | p.A514P | P41743 | protein_coding | tolerated(0.21) | benign(0.437) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
PRKCI | SNV | Missense_Mutation | | c.1745N>G | p.Phe582Cys | p.F582C | P41743 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
PRKCI | deletion | Frame_Shift_Del | novel | c.1551delN | p.Gly518AspfsTer12 | p.G518Dfs*12 | P41743 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
PRKCI | SNV | Missense_Mutation | novel | c.238G>A | p.Val80Ile | p.V80I | P41743 | protein_coding | tolerated(1) | benign(0.024) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRKCI | SNV | Missense_Mutation | novel | c.697G>C | p.Glu233Gln | p.E233Q | P41743 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
PRKCI | SNV | Missense_Mutation | | c.862N>C | p.Glu288Gln | p.E288Q | P41743 | protein_coding | tolerated(0.06) | possibly_damaging(0.837) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.318N>G | p.Phe106Leu | p.F106L | P41743 | protein_coding | tolerated(0.09) | probably_damaging(0.999) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.157N>C | p.Glu53Gln | p.E53Q | P41743 | protein_coding | tolerated(0.11) | possibly_damaging(0.751) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.1376N>T | p.Ser459Phe | p.S459F | P41743 | protein_coding | tolerated(0.06) | possibly_damaging(0.878) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.880G>A | p.Glu294Lys | p.E294K | P41743 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GSK-269962A | GSK-269962A | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | ILORASERTIB | ILORASERTIB | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL608533 | MIDOSTAURIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | SOPHORETIN | QUERCETIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL3545332 | CEP-2563 | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 135652717 | STAUROSPORINE | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL574737 | UCN-01 | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | SOTRASTAURIN | SOTRASTAURIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL565612 | SOTRASTAURIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | INGENOL MEBUTATE | | |